MediPharm Labs Addresses Shareholders as Meeting Approaches
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ), a leader in precision-based cannabinoid products, is reaching out to its valued shareholders regarding recent communications from Apollo Technology Capital Corporation. These communications have prematurely characterized the results of the upcoming annual and special meeting of shareholders as a victory for Apollo. It’s important for our shareholders to understand that the meeting, scheduled for 3:00 p.m., is yet to occur, and therefore, no results are available.
MediPharm is committed to maintaining transparency. Once the meeting concludes, we will provide the final results in accordance with regulatory requirements and Toronto Stock Exchange rules. This commitment reflects our dedication to upholding the trust of our shareholders.
About MediPharm Labs: A Leader in Cannabis Concentrates
Founded in 2015, MediPharm Labs has positioned itself as a pioneer in the pharmaceutical-grade cannabis concentrate industry. Our focus is on developing and manufacturing purified cannabis products with stringent quality controls. Our facilities are compliant with Good Manufacturing Practices (GMP) standards, ensuring that we deliver reliable, high-quality cannabinoid-based products.
With a state-of-the-art manufacturing setup, we continually invest in innovative purification technologies and a highly skilled research team. This investment allows us to produce precision-dosed cannabis products tailored to our customer's needs, both in domestic and international medical markets.
Significant Achievements and Licenses
In our journey, a significant milestone was achieved when we received a Pharmaceutical Drug Establishment License from Health Canada in 2021. This made us the first company in North America with a commercial-scale GMP license for multiple natural cannabinoids extraction. This recognition has been paramount as we pursue FDA registration for foreign drug manufacturing, paving the way for our international operations.
Expansion Through Strategic Acquisitions
The landscape of our business expanded significantly in 2023 when we acquired VIVO Cannabis Inc. This strategic acquisition allowed us to extend our medical services through Canna Farms, enhancing our reach in Canada and entering new markets in Australia and Germany. Furthermore, we integrated Harvest Medical Clinics, which focuses on connecting medical cannabis patients with physicians for consultations, educational resources, and prescriptions.
Commitment to Compliance and Quality
MediPharm Labs operates under a framework of stringent compliance with laws applicable in every country where we operate. This commitment not only upholds our integrity but also reinforces our mission to deliver safe and effective cannabinoid products.
Contacting MediPharm Labs
For any investor-related inquiries, shareholders can reach out to MediPharm Labs Investor Relations at:
Telephone: +1 416.913.7425
Email: investors@medipharmlabs.com
For media inquiries, please contact:
John Vincic
+1 (647) 402-6375
Email: john@oakstrom.com
Frequently Asked Questions
What is the purpose of the MediPharm Labs meeting?
The meeting is to discuss important company matters and update shareholders on progress and plans.
What is MediPharm Labs known for?
MediPharm Labs specializes in precision-based cannabinoid products, focusing on quality and compliance in cannabis manufacturing.
How have recent acquisitions benefited MediPharm Labs?
The acquisition of VIVO Cannabis Inc. allowed for expansion into new markets and enhanced medical services for patients.
What regulatory approvals does MediPharm Labs hold?
MediPharm holds GMP licenses and a Pharmaceutical Drug Establishment License from Health Canada, essential for its operations.
How can investors contact MediPharm Labs?
Investors can reach MediPharm Labs through their Investor Relations email or by phone listed above.
